LPL Financial’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
LPL Financial's LUCD Position: Q2 2026 in Review
LPL Financial reduced its Lucid Diagnostics (LUCD) stake by 23% in Q2 2026, selling an estimated $42.3K and leaving 133,155 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #5846.
LPL Financial first reported a position in LUCD in Q2 2022 and has held it in 17 quarters since. The position peaked at $198K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- LPL Financial held 133,155 shares of Lucid Diagnostics worth $142K as of Q2 2026.
- LPL Financial sold 39,221 Lucid Diagnostics shares in Q2 2026, an estimated $42.3K.
- Lucid Diagnostics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5846 holding.
- LPL Financial first reported a position in Lucid Diagnostics in Q2 2022 and has held it in 17 quarters since.
- LPL Financial's Lucid Diagnostics position peaked at $198K in Q1 2026.
- 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.